Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AMLCourtney D. DiNardo, Hagop M. Kantarjian, Gabrielle T. Prince et al.|New England Journal of Medicine|2018Cited by 1.4k
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyMargaret O’Donnell, Ndiya Ogba, Martin S. Tallman et al.|Journal of the National Comprehensive Cancer Network|2017Cited by 655
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United StatesLori Muffly, William A. Wood, Marcelo C. Pasquini et al.|Blood|2017Cited by 296
Venetoclax plus hypomethylating agent in blast‐phase myeloproliferative neoplasm: preliminary experience with 12 patientsNaseema Gangat, Ayalew Tefferi, Erika Morsia et al.|British Journal of Haematology|2020Cited by 20
Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed <i>FLT3</i> Mutated AMLSelina M. Luger, Mark R. Litzow, Li Chen et al.|Blood|2024Cited by 7